| | Clinical features | Membrane-bound molecules | Soluble molecules | | Baseline () | Remission () | Relapse () | HC () | value | Baseline () | Remission () | Relapse () | HC () | value |
| | Age (years) | 49.0 (37.0, 63.0) | 46.0 (36.0, 58.0) | 48.0 (32.0, 58.0) | 47.0 (32.5, 58.5) | 0.754 | 43.0 (33.0, 66.0) | 39.0 (34.0, 57.0) | 50.5 (40.0, 62.0) | 44.5 (34.0, 54.0) | 0.258 | | Age of onset, (%) | | | | | | | | | | | | EOMG () | 13 (33.3) | 17 (40.4) | 12 (54.6) | n.a. | 0.269 | 16 (43.2) | 19 (63.3) | 16 (47.1) | n.a. | 0.233 | | LOMG () | 9 (23.1) | 18 (42.9) | 8 (36.4) | n.a. | 0.165 | 16 (43.2) | 11 (36.7) | 18 (52.9) | n.a. | 0.417 | | Sex, (%) | | | | | 0.557 | | | | | 0.141 | | Female | 20 (51.3) | 27 (64.3) | 14 (63.6) | 19 (52.8) | | 19 (51.3) | 21 (70.0) | 20 (58.8) | 23 (76.7) | | | Male | 19 (49.7) | 15 (35.7) | 8 (36.4) | 17 (47.2) | | 18 (48.7) | 9 (30.0) | 14 (41.2) | 7 (23.3) | | | MGFA classification, (%) | | | | | 0.001 | | | | | ≤0.001 | | OMG | 25 (64.1) | 30 (71.4) | 3 (13.6) | n.a. | | 22 (59.5) | 19 (63.3) | 3 (8.8) | n.a. | | | GMG | 14 (35.9) | 12 (28.6) | 19 (86.4) | n.a. | | 15 (40.5) | 11 (36.7) | 31 (91.2) | n.a. | | | Thymoma, (%) | | | | | 0.061 | | | | | 0.005 | | Without | 32 (82.1) | 35 (83.3) | 13 (59.1) | n.a. | | 27 (73.0) | 21 (70.0) | 13 (38.2) | n.a. | | | With | 7 (17.9) | 7 (16.7) | 9 (40.9) | n.a. | | 10 (27.0) | 9 (30.0) | 21 (61.8) | n.a. | | | AchR-Ab, (%) | | | | | 0.003 | | | | | 1.000 | | Positive, (%) | 22 (56.4) | 35 (83.3) | 20 (90.9) | n.a. | | 32 (86.5) | 30 (100.0) | 34 (100.0) | n.a. | | | Negative, (%) | 19 (43.6) | 7 (16.7) | 2 (9.1) | n.a. | | 5 (13.5) | 0 (0.0) | 0 (0.0) | n.a. | | | Disease duration (months) | 3 (1.0, 24.0) | 22.5 (8.0, 46.0) | 22 (7.0, 40.0) | n.a. | ≤0.001 | 1 (1.0, 2.0) | 15 (10.0, 38.0) | 20 (3.0, 52.0) | n.a. | ≤0.001 | | QMGs | 7.0 (5.0, 10.5) | 7.0 (4.0, 8.0) | 13.0 (11.0, 18.0) | n.a. | ≤0.001 | 8.0 (6.0, 12.0) | 7.0 (6.0, 9.0) | 14.0 (12.0, 20.0) | n.a. | ≤0.001 |
|
|
